Mackenzie Financial Corp Makes New Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Mackenzie Financial Corp bought a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZGet Rating) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 10,805 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,686,000.

A number of other hedge funds have also bought and sold shares of JAZZ. State of New Jersey Common Pension Fund D increased its position in shares of Jazz Pharmaceuticals by 4.3% during the 1st quarter. State of New Jersey Common Pension Fund D now owns 35,262 shares of the specialty pharmaceutical company’s stock valued at $5,489,000 after purchasing an additional 1,445 shares during the last quarter. Arizona State Retirement System increased its position in shares of Jazz Pharmaceuticals by 2.8% during the 1st quarter. Arizona State Retirement System now owns 17,111 shares of the specialty pharmaceutical company’s stock valued at $2,664,000 after purchasing an additional 460 shares during the last quarter. Envestnet Asset Management Inc. increased its position in shares of Jazz Pharmaceuticals by 0.6% during the 1st quarter. Envestnet Asset Management Inc. now owns 40,976 shares of the specialty pharmaceutical company’s stock valued at $6,379,000 after purchasing an additional 239 shares during the last quarter. Commonwealth Equity Services LLC increased its position in shares of Jazz Pharmaceuticals by 4.6% during the 1st quarter. Commonwealth Equity Services LLC now owns 10,167 shares of the specialty pharmaceutical company’s stock valued at $1,582,000 after purchasing an additional 447 shares during the last quarter. Finally, Dearborn Partners LLC purchased a new stake in shares of Jazz Pharmaceuticals during the 1st quarter valued at about $211,000. Hedge funds and other institutional investors own 92.79% of the company’s stock.

Jazz Pharmaceuticals Trading Up 2.9 %

JAZZ stock opened at $153.21 on Wednesday. Jazz Pharmaceuticals plc has a 1-year low of $117.64 and a 1-year high of $169.98. The company has a debt-to-equity ratio of 2.07, a current ratio of 3.16 and a quick ratio of 2.27. The company has a market capitalization of $9.65 billion, a price-to-earnings ratio of -510.70, a PEG ratio of 0.88 and a beta of 0.74. The business has a 50 day simple moving average of $139.57 and a two-hundred day simple moving average of $148.14.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. UBS Group reduced their price target on shares of Jazz Pharmaceuticals from $194.00 to $191.00 and set a “buy” rating for the company in a research report on Thursday, August 4th. Morgan Stanley upped their price target on shares of Jazz Pharmaceuticals from $174.00 to $187.00 and gave the company an “equal weight” rating in a research report on Thursday, August 4th. HC Wainwright reduced their price target on shares of Jazz Pharmaceuticals from $210.00 to $204.00 in a research report on Friday, August 5th. SVB Leerink upped their price target on shares of Jazz Pharmaceuticals from $200.00 to $210.00 and gave the company an “outperform” rating in a research report on Thursday, August 4th. Finally, StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $202.50.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, SVP Finbar Larkin sold 197 shares of the company’s stock in a transaction that occurred on Monday, November 14th. The stock was sold at an average price of $149.33, for a total value of $29,418.01. Following the completion of the transaction, the senior vice president now directly owns 19,409 shares in the company, valued at approximately $2,898,345.97. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Bruce C. Cozadd sold 45,185 shares of the stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $134.93, for a total transaction of $6,096,812.05. Following the completion of the transaction, the chief executive officer now directly owns 374,028 shares in the company, valued at approximately $50,467,598.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Finbar Larkin sold 197 shares of the stock in a transaction that occurred on Monday, November 14th. The shares were sold at an average price of $149.33, for a total value of $29,418.01. Following the transaction, the senior vice president now owns 19,409 shares of the company’s stock, valued at $2,898,345.97. The disclosure for this sale can be found here. Insiders sold 56,211 shares of company stock worth $7,780,391 in the last three months. 4.40% of the stock is owned by company insiders.

Jazz Pharmaceuticals Profile

(Get Rating)

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca.

Recommended Stories

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.